A phase 3 trial also evaluated CEACAM5-DM4 ADC compared to docetaxel in NSQ NSCLC after failure of first-line treatment, but study endpoint was not reached and trial was discontinued [73]. Here, CEACAM5 is linked to non-small cell lung carcinoma.